Publicacións en colaboración con investigadores/as de Eli Lilly and Company (9)

2023

  1. Persistence and Use of Ixekizumab in Patients with Psoriatic Arthritis in Real-World Practice in Spain. The PRO-STIP Study

    Rheumatology and Therapy, Vol. 10, Núm. 5, pp. 1319-1333

2022

  1. Development and external validation of prediction models for adverse health outcomes in rheumatoid arthritis: A multinational real-world cohort analysis

    Seminars in Arthritis and Rheumatism, Vol. 56

  2. Response to: 'Use of tanezumab for patients with hip and knee osteoarthritis with reference to a randomised clinical trial by Berenbaum and colleagues' by Riddle and Perera

    Annals of the Rheumatic Diseases

2021

  1. Integrative Analysis Reveals a Molecular Stratification of Systemic Autoimmune Diseases

    Arthritis and Rheumatology, Vol. 73, Núm. 6, pp. 1073-1085

  2. Subcutaneous tanezumab for osteoarthritis: Is the early improvement in pain and function meaningful and sustained?

    European Journal of Pain (United Kingdom), Vol. 25, Núm. 7, pp. 1525-1539

2020

  1. Subcutaneous tanezumab for osteoarthritis of the hip or knee: Efficacy and safety results from a 24-week randomised phase III study with a 24-week follow-up period

    Annals of the Rheumatic Diseases, Vol. 79, Núm. 6, pp. 800-810

  2. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety

    Pain, Vol. 161, Núm. 9, pp. 2068-2078

2018

  1. Efficacy and safety of guselkumab in patients with active psoriatic arthritis: a randomised, double-blind, placebo-controlled, phase 2 study

    The Lancet, Vol. 391, Núm. 10136, pp. 2213-2224

2015

  1. Prevalence of fractures in women with rheumatoid arthritis and/or systemic lupus erythematosus on chronic glucocorticoid therapy Epidemiology of musculoskeletal disorders

    BMC Musculoskeletal Disorders, Vol. 16, Núm. 1